Modern healthcare systems are still largely designed to react to illness after symptoms appear rather than prevent disease before it develops. Millions of people undergo medical treatment only after conditions have already progressed, despite growing scientific evidence showing that earlier detection and continuous monitoring can significantly improve long term health outcomes. Preventive health startup Lucis is building an AI powered platform designed to shift healthcare toward earlier intervention through biomarker analysis, personalised recommendations, and longitudinal monitoring, and the company has now secured major funding to accelerate expansion across Europe.
Lucis has raised $20 million in a Series A funding round led by Singular, with participation from General Catalyst, Y Combinator, and several angel investors including backers behind Runna.
The latest financing follows an $8 million seed round raised just four months earlier, bringing Lucis’s total funding to $28 million.
Building a Data Driven Preventive Health Platform
Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis provides users with comprehensive health analysis built around biomarker testing and AI powered recommendations.
The platform analyses more than 110 blood biomarkers spanning areas including metabolic health, cardiovascular risk, hormones, inflammation, and nutrient levels.
These biomarker results are combined with longitudinal health data and medical context inside an AI powered health companion application that generates personalised guidance around nutrition, supplementation, lifestyle adjustments, and follow up testing.
According to the company, recommendations continuously evolve as additional health data becomes available and are reviewed by physicians to maintain clinical oversight.
Shifting Healthcare Toward Prevention
Maxime Berthelot said the current healthcare system remains heavily focused on treating illness after symptoms emerge rather than identifying risks earlier through preventive monitoring.
According to Berthelot, Lucis was created to help close that gap by combining biomarker analysis with AI driven clinical insights capable of identifying health issues before symptoms become severe.
The company believes Europe needs a healthcare model where prevention becomes the default approach rather than a premium service accessible only to a small portion of the population.
Early Data Shows Strong Engagement
Lucis says early data from its growing user base demonstrates both strong engagement and measurable health improvements.
Among users who completed six month follow up testing, approximately 75 percent improved at least three biomarkers without medication.
Meanwhile, more than 80 percent chose to continue retesting, suggesting sustained engagement with both the platform and their long term health monitoring.
The company also reported that nearly all users tested had at least one biomarker outside optimal ranges during initial assessments, often without prior awareness of potential health risks.
Lucis believes this highlights how easily underlying health issues can remain undetected without regular monitoring and personalised analysis.
Expanding Across Europe
Since launching in 2025, Lucis has grown to more than 10,000 users across France, the United Kingdom, Ireland, and Portugal.
The platform has already delivered more than one million biomarker tests while building partnerships with laboratory groups including Eurofins and Randox.
Today, the company operates with a team of 20 employees spanning engineering, clinical operations, growth, and support functions alongside a medical board and a growing network of physicians.
Building the Future of Preventive Healthcare
Jeremy Uzan said Europe’s preventive health sector will likely be shaped by platforms capable of combining clinical credibility with scalable AI infrastructure.
The newly secured funding will support Lucis’s expansion into Spain, Germany, and Italy by the end of 2026 while helping the company continue investing in personalisation, longitudinal monitoring, and clinical safety systems.
As healthcare increasingly moves toward data driven prevention and continuous monitoring, platforms capable of combining AI analysis, biomarker intelligence, and medical oversight are becoming an increasingly important part of the future healthcare ecosystem.
